AKT1 and osteosarcoma: Mechanistic studies revealed that TRIM17 promotes ubiquitination and degradation of FTO, enhances PDK1 mRNA stability through m6A modification, activates the AKT/mTOR signaling pathway, and drives osteosarcoma cell clonability and survival potential and invasion, thereby contributing to osteosarcoma progression.